Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells

Chimeric antigen receptor (CAR) T cell therapy has shown promising responses in patients with refractory or relapsed aggressive B-cell malignancies that are resistant to conventional chemotherapy or stem cell transplantation. A potentially combinatorial therapeutic strategy may be the inhibition of...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Mingya, Wang, Lei, Ni, Ming, Neuber, Brigitte, Wang, Sanmei, Gong, Wenjie, Sauer, Tim, Sellner, Leopold, Schubert, Maria-Luisa, Hückelhoven-Krauss, Angela, Hong, Jian, Zhu, Lixin, Kleist, Christian, Eckstein, Volker, Müller-Tidow, Carsten, Dreger, Peter, Schmitt, Michael, Schmitt, Anita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756123/
https://www.ncbi.nlm.nih.gov/pubmed/33362794
http://dx.doi.org/10.3389/fimmu.2020.608167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756123/
https://www.ncbi.nlm.nih.gov/pubmed/33362794
http://dx.doi.org/10.3389/fimmu.2020.608167

Ejemplares similares